EloraTZP
eloralintide + tirzepatide · Eli Lilly
Eloralintide is added to tirzepatide as a distinct obesity strategy.
Selected study results
EloraTZP Phase 2bMean body-weight change · primary endpointBody weight decreased 23.3% · 48 weeks · Phase 2b
Mean body-weight change · primary endpoint · 48 weeks
Study focus: Weight management with type 2 diabetes
Adults with obesity or overweight and type 2 diabetes · Once weekly, as separate injections · Trial N=367 · Efficacy estimand; sponsor-reported EASD results. Results & methods ↗
| Weekly regimen | Weight change | HbA1c change (pp) |
|---|---|---|
| Eloralintide 3 mg + tirzepatide 5 mg | −13.2% | −2.2 |
| Eloralintide 6 mg + tirzepatide 5 mg | −19.4% | −2.7 |
| Eloralintide 6 mg + tirzepatide 10 mg | −19.9% | −2.6 |
| Eloralintide 9 mg + tirzepatide 15 mg | −23.3% | −2.9 |
| Tirzepatide 15 mg | −14.8% | −2.4 |
| Eloralintide 3 mg | −8.2% | −1.1 |
| Eloralintide 6 mg | −12.3% | −1.4 |
| Eloralintide 9 mg | −11.1% | −1.3 |
| Placebo | −3.0% | −0.3 |
Primary comparison: combination versus placebo; comparisons with tirzepatide were secondary. Baseline mean weight 105.4 kg and HbA1c 8.1%. These results have not been verified against a journal publication.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Safety context
Adverse-event discontinuation: 10.8–27.0% across combination arms, 0–10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo. The combination range is not assigned to individual doses.
Mechanism at a glance
Obesity stage by formulation
Latest: AMPLIFY-2 Phase 3 began October 16, 2026, and is recruiting per the November 4 registry update. The separate AMPLIFY-1 Phase 3 study is registered, not yet recruiting.
Next: Phase 3 AMPLIFY recruitment and outcomes; the reported Phase 2b study used separate injections.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
AMPLIFY-1
Weight management without type 2 diabetesRegistered Phase 3 in an estimated 2,115 adults with obesity without type 2 diabetes; week-100 weight endpoint, not yet recruiting, with an estimated December 2026 start.
AMPLIFY-2
Combination weight management with type 2 diabetesPhase 3 in an estimated 1,000 adults with overweight or obesity and type 2 diabetes; EloraTZP versus tirzepatide, with a week-100 weight endpoint. Actual start October 16, 2026.
Phase 2 studies1 record
EloraTZP type 2 diabetes study
Combination weight management with type 2 diabetes48-week randomized, double-blind Phase 2b study in 367 adults with overweight or obesity and type 2 diabetes; separate injections. Primary weight comparison with placebo; other comparisons secondary.
Related conditions and outcomes
Phase 2 studies1 record
Eloralintide + tirzepatide study
Combination developmentRegistered study of eloralintide and eloralintide plus tirzepatide in adults with overweight or obesity; see registry for design details.
